Pharma BD Deal Intelligence
A co-development partnership that produced the first-in-class BCL-2 inhibitor venetoclax (Venclexta), rewriting treatment paradigms for CLL and AML. AbbVie and Genentech split US commercialization while AbbVie took exclusive ex-US rights—shared clinical risk, multi-billion-dollar revenue.
Venetoclax is a BCL-2 inhibitor co-developed by AbbVie and Genentech Roche through collaboration valued at $500 million including milestones
Anti-cancer treatment venetoclax yields US$325M in landmark Australian deal originating from AbbVie-Genentech collaboration research
FDA approves Genentech and AbbVie Venclexta venetoclax combination to treat AML demonstrating success of BCL-2 inhibitor co-development
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Abbott Laboratories and Genentech entered a co-development and co-commercialization collaboration for two oncology compounds: ABT-263 (navitoclax, BCL-2 family inhibitor) and ABT-869 (linifanib, multi-kinase inhibitor). The collaboration was later expanded to cover ABT-199 (venetoclax/Venclexta), a re-engineered selective BCL-2 inhibitor for hematologic malignancies. Companies agreed to share development costs globally and co-promote any resulting products in the United States; Abbott to promote outside the U.S. AbbVie inherited the collaboration after spinning off from Abbott in January 2013. Specific financial terms not disclosed.
21K US cases/yr · $7.5B Global CLL Market (2017)
Venetoclax was the first BCL-2 inhibitor approved for cancer, restoring apoptosis in CLL cells. It enabled chemo-free, fixed-duration combinations achieving MRD-negative remissions.
AbbVie and Genentech co-commercialize in the US. Venclexta exceeded $2.5B globally in 2023, with continued growth from fixed-duration frontline CLL use.
20K US cases/yr · $2.8B Global AML Market (2019) · ~75% AML Patients Ineligible for Chemo
~50-60%
Venetoclax + HMA approved 2018, establishing the ven-aza backbone as standard frontline therapy for unfit AML patients.
AbbVie and Genentech/Roche established co-development for venetoclax (BCL-2 inhibitor) in hematologic malignancies.
Venclexta generated $3.347B globally in 2024. AbbVie commercializes outside US; Genentech in US.
Venclexta approved in CLL/SML and AML. $3.35B annual sales. Multiple ongoing expansion trials.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Genentech, Inc. (Roche Group) (this deal) | 2007 | — | 79 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2007 deals · Abbott Laboratories deals · Oncology deals